As of 2024-12-15, the Relative Valuation of Royalty Pharma PLC (RPRX) is 57.96 USD. This relative valuation is based on P/E multiples. With the latest stock price at 24.84 USD, the upside of Royalty Pharma PLC based on Relative Valuation is 133.3%.
The range of the Relative Valuation is 52.71 - 59.78 USD.
| Range | Selected | |
| Trailing P/E multiples | 27.1x - 30.8x | 29.2x |
| Forward P/E multiples | 27.5x - 29.3x | 29.2x |
| Fair Price | 52.71 - 59.78 | 57.96 |
| Upside | 112.2% - 140.7% | 133.3% |
| Date | P/E |
| 2024-12-13 | 12.78 |
| 2024-12-12 | 12.97 |
| 2024-12-11 | 12.97 |
| 2024-12-10 | 13.17 |
| 2024-12-09 | 13.38 |
| 2024-12-06 | 13.33 |
| 2024-12-05 | 13.58 |
| 2024-12-04 | 13.43 |
| 2024-12-03 | 13.55 |
| 2024-12-02 | 13.60 |
| 2024-11-29 | 13.72 |
| 2024-11-27 | 13.69 |
| 2024-11-26 | 13.53 |
| 2024-11-25 | 13.62 |
| 2024-11-22 | 13.60 |
| 2024-11-21 | 13.58 |
| 2024-11-20 | 13.49 |
| 2024-11-19 | 13.38 |
| 2024-11-18 | 13.27 |
| 2024-11-15 | 13.22 |
| 2024-11-14 | 13.16 |
| 2024-11-13 | 13.30 |
| 2024-11-12 | 13.38 |
| 2024-11-11 | 13.56 |
| 2024-11-08 | 13.49 |
| 2024-11-07 | 13.65 |
| 2024-11-06 | 13.71 |
| 2024-11-05 | 14.17 |
| 2024-11-04 | 13.99 |
| 2024-11-01 | 13.94 |
| 2024-10-31 | 13.89 |
| 2024-10-30 | 13.99 |
| 2024-10-29 | 13.97 |
| 2024-10-28 | 14.03 |
| 2024-10-25 | 13.87 |
| 2024-10-24 | 14.04 |
| 2024-10-23 | 14.08 |
| 2024-10-22 | 14.08 |
| 2024-10-21 | 14.28 |
| 2024-10-18 | 14.40 |
| 2024-10-17 | 14.43 |
| 2024-10-16 | 14.52 |
| 2024-10-15 | 14.32 |
| 2024-10-14 | 14.34 |
| 2024-10-11 | 14.42 |
| 2024-10-10 | 14.14 |
| 2024-10-09 | 14.19 |
| 2024-10-08 | 14.08 |
| 2024-10-07 | 14.19 |
| 2024-10-04 | 14.28 |